Cancer metabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliers

Drug development groups are close to discovering another pot of gold-a therapeutic target-similar to the success of imatinib (Gleevec) in the field of cancer biology. Modern molecular biology has improved cancer therapy through the identification of more pharmaceutically viable targets, and yet majo...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules & therapeutics Vol. 23; no. 2; pp. 99 - 109
Main Author Kim, Soo-Youl
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society of Applied Pharmacology 01.03.2015
한국응용약물학회
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Drug development groups are close to discovering another pot of gold-a therapeutic target-similar to the success of imatinib (Gleevec) in the field of cancer biology. Modern molecular biology has improved cancer therapy through the identification of more pharmaceutically viable targets, and yet major problems and risks associated with late-phase cancer therapy remain. Presently, a growing number of reports have initiated a discussion about the benefits of metabolic regulation in cancers. The Warburg effect, a great discovery approximately 70 years ago, addresses the "universality" of cancer characteristics. For instance, most cancer cells prefer aerobic glycolysis instead of mitochondrial respiration. Recently, cancer metabolism has been explained not only by metabolites but also through modern molecular and chemical biological techniques. Scientists are seeking context-dependent universality among cancer types according to metabolic and enzymatic pathway signatures. This review presents current cancer metabolism studies and discusses future directions in cancer therapy targeting bio-energetics, bio-anabolism, and autophagy, emphasizing the important contribution of cancer metabolism in cancer therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
G704-000363.2015.23.2.012
ISSN:1976-9148
2005-4483
1976-9148
2005-4483
DOI:10.4062/biomolther.2015.013